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Panel-based NGS Reveals Novel 
Pathogenic Mutations in Autosomal 
Recessive Retinitis Pigmentosa
Raquel Perez-Carro1,2, Marta Corton1,2, Iker Sánchez-Navarro1,2, Olga Zurita1,2, 
Noelia Sanchez-Bolivar1,2, Rocío Sánchez-Alcudia1,2, Stefan H. Lelieveld3, Elena Aller2,4, 
Miguel Angel Lopez-Martinez1,2, Mª Isabel López-Molina5, Patricia Fernandez-San 
Jose1,2, Fiona Blanco-Kelly1,2, Rosa Riveiro-Alvarez1,2, Christian Gilissen3, Jose M Millan2,4, 
Almudena Avila-Fernandez1,2,* & Carmen Ayuso1,2,*
Retinitis pigmentosa (RP) is a group of inherited progressive retinal dystrophies (RD) characterized 
by photoreceptor degeneration. RP is highly heterogeneous both clinically and genetically, which 
complicates the identification of causative genes and mutations. Targeted next-generation sequencing 
(NGS) has been demonstrated to be an effective strategy for the detection of mutations in RP. In 
our study, an in-house gene panel comprising 75 known RP genes was used to analyze a cohort of 
47 unrelated Spanish families pre-classified as autosomal recessive or isolated RP. Disease-causing 
mutations were found in 27 out of 47 cases achieving a mutation detection rate of 57.4%. In total, 33 
pathogenic mutations were identified, 20 of which were novel mutations (60.6%). Furthermore, not 
only single nucleotide variations but also copy-number variations, including three large deletions in 
the USH2A and EYS genes, were identified. Finally seven out of 27 families, displaying mutations in 
the ABCA4, RP1, RP2 and USH2A genes, could be genetically or clinically reclassified. These results 
demonstrate the potential of our panel-based NGS strategy in RP diagnosis.
Retinitis pigmentosa (RP, MIM 268000) is the most common form of inherited retinal degeneration with a prev-
alence of 1 in 4000 individuals1. RP is characterized by primary rod degeneration leading to night blindness, 
the development of tunnel vision and slow progressive decrease in central vision2. However, the disease onset, 
progression, retinal appearance, and final visual outcome may vary significantly among patients, even within the 
same family3. RP is also a highly heterogeneous genetic disorder; the disease can be inherited in different forms 
including autosomal dominant (adRP) in about 20-40% of the cases, autosomal recessive (arRP) in 30-50% or 
X-linked trait (xlRP) in 5-15% of the cases. Sporadic cases (sRP) account for about 40% of all diagnoses, although 
these percentages vary between different populations4,5. Non-Mendelian inheritance patterns such as digenic, 
mitochondrial or de novo mutations have been also reported, though these account for a minor proportion of 
cases6,7.
Hitherto, nearly 3100 pathogenic mutations have been reported8,9 in more than 80 genes associated with 
non-syndromic RP and 55 of them have been related to autosomal recessive RP (arRP) (RetNet; update Aug 2015 
https://sph.uth.edu/retnet/). Although the functions of some of these genes have been extensively studied, it is 
difficult to establish a precise genotype-phenotype correlation, due to the fact that several genes cause distinct or 
partially overlapping clinical phenotypes6.
Genetic diagnosis of the RD has been mainly based on either the use of the specific genotyping microar-
rays—for which the mutation detection rate ranges from 11% to 70% depending on the RD form10–12—or on a 
gene-by-gene analysis by Sanger sequencing for mutation screening which is time-consuming and expensive.
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Despite the difficulties, the molecular diagnosis of patients affected with RD provides them a number of ben-
efits as it can supply an accurate prognosis of the clinical course of the disease and appropriate genetic counseling 
to the families. In addition, the molecular characterization of patients allows future inclusion in clinical trials 
based on gene therapy.
In the last few years, the development of high-throughput technologies, such as next-generation sequencing 
(NGS), has allowed to screen a large number of genes. Simultaneously, this technique offers a high sensitivity and 
efficiency making the molecular diagnosis of this heterogeneous disease easier.
NGS is currently considered the most efficient method for mutation screening. Recent studies in different 
populations demonstrated the great potential of NGS technologies as a diagnostic tool in the field of RD charac-
terizing around 30-60% of cases9,13.
Herein, we report an in-house targeted gene panel developed to be an efficient and feasible tool for molecular 
diagnosis. Using this approach we were able to study 47 unrelated Spanish families affected by arRP. In addi-
tion, this strategy allowed us to amplify the mutational spectrum identifying not only point mutations but also 
copy-number variations (CNV), thereby further increasing the diagnostic yield.
Results
Next generation sequencing experiments were run on the Illumina MiSeq platform using 150 bp paired-end 
reads. On average 2,971,800 reads per patient were generated. On average the base-pairs of the genes present in 
the panel were covered by 722 times (range [92x-2911x]) and 99.1% of the base-pairs in coding regions of the 
75 RD genes were covered by at least 10 reads. In addition, for 73.5% of the genes all of the base-pairs were cov-
ered by 10 reads or more. A complete overview of the coverage of each gene is shown in Fig. 1.
Because of high GC content and/or repetitive elements it was impossible to design efficient probes in seven 
specific regions (Supp. Table 1) of the genes: CERKL, CA4, RP2, SNRNP200, CEP290 and EYS. All of these exons 
were additionally analyzed by Sanger sequencing though no mutations were found among the uncharacterized 
patients.
Validation of the panel-based NGS. In order to verify the reliability of our NGS approach, we used a val-
idation cohort consisting of 24 out of the total 47 patients analyzed, who had different heterozygous variants (17 
mutations and 7 polymorphisms) previously identified by a genotyping microarray (Asper Biotech). Our strategy 
allowed us to redetect all the variants found and previously checked by Sanger sequencing giving us a sensitivity 
of 100% for those validation variants (Table 1).
Genetic findings in 47 RP patients. For the 47 unrelated RP families analyzed, a total of 27 were molecu-
larly characterized using our NGS strategy, reaching a diagnosis detection rate of 57.4% (Table 1).
Figure 1. Coverage Boxplot. Overview of 75 genes and the percentage of coding bases covered by at least 
10 reads. For each of the 75 genes the percentage of bases not covered by 10 or more reads is shown for the 47 
samples. The green colored box indicate the first and third quantile and the black horizontal bar within the box 
illustrate the median (or second quantile). Measurements are considered outliers (black dots in plot) when they 
are: 1) less than the first quantile – 1.5xIQR or 2) greater than the third quantile + 1.5 × IQR, were the IQR is the 
“Inter quantile range” (Third quantile – first quantile).
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After applying the filtering criteria better described in Methods section—which included the in silico predic-
tion analysis (Table 2) and based upon the segregation analysis and the absence of those missense and splice-site 
novel variants in the healthy Spanish population—a total of 33 different variants were considered as causative 
mutations. All the variants considered as causative in the complete cohort were confirmed by Sanger sequencing 
therefore no false positives were found giving us a specificity of 100%.
Twenty of these causative mutations (60.6%), located in the ABCA4, CERKL, CNGA1, EYS, PDE6A, PRCD, 
RDH12, RP1, RP2 and USH2A genes, were novel (Table 1).
Among the identified variants, 45.4% (15/33) were loss-of-function (LOF) mutations including six nonsense 
and nine frameshift mutations and 6% (2/33) were splice-site mutations. Approximately one-third (39.4%; 13/33) 
of the detected mutations were missense variants. Furthermore, three large deletions of one or more exons were 
found in the USH2A and EYS genes in the families RP-1706, RP-1929 and RP-2112.
In 13 out of the 27 characterized families (48.1%) one allele was previously identified by the genotyping 
microarray and we were able to find the second allele applying our NGS approach. For the remaining 14 charac-
terized families (51.9%) with no previous known variation, causative mutations were found with our NGS strat-
egy thereby establishing a molecular diagnosis. Three families with a previous mutation were not diagnosed with 
a second causative mutated allele whereas the fourth family with a previous mutation in USH2A (p.Cys759Phe) 
was finally diagnosed with a mutation in the RP1 gene (RP-1772).
Based on our genetic screening, a total of seven out of the 27 cases could be reclassified. Five of them were 
clinically reclassified after the genetic screening. Four turned out to be atypical Usher syndrome: adult-onset 
mild neurosensorial hearing loss (RP-1735, RP-1979, RP-0338 and RP-0344 with mutations in USH2A) and one 
cone-rod dystrophy (CRD) (RP-1543 with mutations in ABCA4). The other two remained with the diagnosis of 
RP but turned out to be an X-linked (xlRP) and autosomal dominant retinitis pigmentosa (adRP) with mutations 
in RP2 (RP-1201) and RP1 (RP-1772) respectively (Table 1). The clinical information of all index cases of charac-
terized families is shown in Supp. Table 2.
Family Gene
Allele 1 Allele 2
Nucleotide 
change Protein Change Methods Reference Nucleotide change Protein Change Methods Reference Segregation
RP-1147 CNGA1 c.94C > T p.Arg32* aC Paloma (2002) c.830G > A p.Arg277Gln H This study Yes
RP-2066 PDE6A c.1705C > A p.Gln569Lys aC Dryja (1999) c.1620 + 1G > T splicing defect H This study NA
RP-2114 RDH12 c.278T > C p.Leu93Pro aC Avila-Fernandez (2010) c.210–211insC p.Arg71Glnfs*12 H This study NA
RP-1319 USH2A c.2276G > T p.Cys759Phe aC Rivolta (2000) c.920–923dupGCCA p.His308Glnfs*16 H Weston (2000) NA
RP-1412 USH2A c.2276G > T p.Cys759Phe aC Rivolta (2000) c.1214delA p.Asn405Ilefs*3 H Schwartz (2005) Yes
RP-1646 USH2A c.2276G > T p.Cys759Phe aC Rivolta (2000) c.12575G > A p.Arg4192His H Avila-Fernandez (2010) Yes
RP-1695 USH2A c.2276G > T p.Cys759Phe aC Rivolta (2000) c.9799T > C p.Cys3267Arg H Aller (2006) NA
RP-1735 USH2A c.2276G > T p.Cys759Phe aC Rivolta (2000)
c.12153–12175delAAT
TTTAAGCCCTTGGA
CTCTGA
p.Glu4051Aspfs*40 H This study NA
RP-1802 USH2A c.2276G > T p.Cys759Phe aC Rivolta (2000) c.920–923dupGCCA p.His308Glnfs*16 H Weston (2000) Yes
RP-1976 USH2A c.2276G > T p.Cys759Phe aC Rivolta (2000) c.8254G > A p.Gly2752Arg H Nakanishi (2009) NA
RP-1979 USH2A c.2276G > T p.Cys759Phe aC Rivolta (2000) c.1606T > C p.Cys536Arg H Dreyer (2000) Yes
RP-2112 USH2A c.2276G > T p.Cys759Phe aC Rivolta (2000) Deletion Ex.45-49 – H Baux (2014) NA
RP-2113 USH2A c.2276G > T p.Cys759Phe aC Rivolta (2000) c.5462A > G p.Lys1821Arg H This study Yes
RP-1543 ABCA4 c.4234C > T p.Gln1412* H Maugeri (1999) c.5917delG p.Val1973* H Rivera (2000) NA
RP-1056 CERKL c.847C > T p.Arg283* H Tuson (2004) c.664C > T p.Gln222* H This study Yes
RP-1998 CNGB1 c.2957A > T p.Asn986Ile H Simpson (2011) c.2957A > T p.Asn986Ile H Simpson (2011) Yes
RP-1706 EYS c.2826–2827delAT p.Val944Glyfs*9 H This study Deletion Ex.19 – H This study Yes
RP-1929 EYS c.9142dupA p.Arg3048Lysfs*9 H This study Deletion Ex.13-14 – H Pieras (2011) NA
RP-1142 GUCY2D c.1762C > T p.Arg588Trp H Stone (2007) c.1762C > T p.Arg588Trp H Stone (2007) Yes
RP-0372 PDE6A c.1957C > T p.Arg653* H This study c.1957C > T p.Arg653* H This study Yes
RP-0040 PRCD c.74 + 1G > A splicing defect H This study c.74 + 1G > A splicing defect H This study Yes
RP-1772 RP1 c.2431delA p.Ser812Valfs*36 H This study Yes
RP-1988 RP1 c.400–401insGC p.His136Argfs*8 H This study c.400–401insGC p.His136Argfs*8 H This study Yes
RP-1201 RP2 c.708C > G p.Cys236Trp H This study Yes
RP-0338 USH2A c.9433C > T p.Leu3145Phe H This study c.9433C > T p.Leu3145Phe H This study Yes
RP-0344 USH2A c.8693A > C p.Tyr2898Ser H de Castro-Miró (2014) c.10008C > A p.Cys3336* H This study Yes
RP-0456 USH2A c.2276G > T p.Cys759Phe H Rivolta (2000) c.10709G > T p.Cys3570Phe H This study NA
Table 1.  Causative mutations identified in 27 characterized autosomal recesive retinitis pigmentosa 
families. Abbreviations: arRP Chip (aC); Haloplex (H). NA: No additional family members available.
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CNV Analysis from High-coverage NGS Data. The high number of readouts obtained by the Illumina 
MiSeq Sequencing for NGS allowed us to perform a quantitative analysis.
Only targeted regions covered by at least 100X, in order to avoid false positive calls, were selected for the CNV 
analysis. After the CNV study carried out in our cohort, five large copy-number changes in a heterozygous state, 
of which two deletions in the EYS gene, one deletion in USH2A and two different duplications in the CEP290 
gene, were detected (Supp. Table 3). The two deletions identified in the EYS gene comprised exons 13-14 (previ-
ously reported) and exon 19 (firstly reported in this study), whereas a deletion from the exon 45 to 49 previously 
reported by Baux et al.14 was detected in USH2A (Table 1). All copy number variants were subsequently validated 
by MLPA (Fig. 2). To check the CEP290 duplications in the RP-0830 family, a customized-aCGH previously 
designed in our group for another purpose15 including several genes was used but the duplications could not be 
confirmed (data not shown).
Uncertain variants and unsolved cases. Novel missense variants predicted as pathogenic were found. 
However their high frequency in Spanish population (SPV database) leads us to classify them as benign (Supp 
Table 4).
For the family RP-1874 only one pathogenic allele, a non-canonical splice site mutation in CNGB1 
(c.2634 + 6G > A) was identified (Table 3). The index case of the RP-1747 family carried two potentially patho-
genic heterozygous mutations in two different genes, EYS (p.Tyr2822Cys) and USH2A (p.Gly1871Asp) however 
no second allele was found (Table 3). Finally, in 17 out of 47 families (36.1%) no candidate variants were found.
Discussion
Recently, the NGS has been proved to be very helpful for carrying out genetic studies in heterogeneous diseases 
such as Retinitis Pigmentosa13,16. In our study, a targeted sequence capture to detect novel pathogenic variants in 
75 known RP genes in 47 arRP Spanish families was performed.
Twenty-seven out of 47 families were solved (detection rate of 57.4%) identifying 33 different mutations. From 
them, 60.6% (20/33) were novel mutations affecting the ABCA4, CERKL, CNGA1, EYS, PDE6A, PRCD, RDH12, 
RP1, RP2 and USH2A genes. All known variants used as positive controls were redetected by this technology 
demonstrating the high specificity and sensitivity of our approach.
Unfortunately, for those cases with only one pathogenic allele or with two heterozygous mutations in different 
genes, cosegregation analysis could not be performed or provided results were inconclusive. Further transcrip-
tional profile studies may clarify the effect of the non-canonical splice-site mutation found in the CNGB1 gene. 
Some authors have claimed to have found evidence of digenic inheritance when they detect two clear mutations 
in two different genes17. However, as has been previously reported, this event is rarely demonstrated, since the 
genetic load of mutations in genes responsible for RP is very high as has been previously reported18. In the family 
RP-1747 that carried two likely pathogenic variants in USH2A and EYS we cannot exclude the presence of a sec-
ond pathogenic allele in deep intronic or other genomic regions that are not systematically analyzed, and a third 
mutation is found by chance in the second gene. Alternatively it could be that the gene responsible for the disease 
had not yet been identified, and the possible modifier effect of the mutations found in the EYS and USH2A genes 
remain to be demonstrated.
According to the molecular results, seven out of 27 families were both clinically and genetically reclassified. In 
order to provide an accurate genetic counseling, disease prognosis and follow up to the families, their reclassifica-
tion is crucial. In addition, it allows to develop new personalized therapies for these families. Since mutations in 
USH2A cause both non-syndromic RP and Usher syndrom19,20, the presence of the mutations in this gene in the 
Missense Variants
Family Gene cDNA Protein SIFT Polyphen Align GVGD Mut.Taster phyloP SPV EVS ExAC
RP-1147 CNGA1 c.1037G > A p.Arg346Gln D(0) Pos. D(0.852) Class C35 D 5.39 – 0.0001 0.00001
RP-1201 RP2 c.708C > G p.Cys236Trp D(0) Pr. D(0.997) Class C65 D -0.149 – – –
RP-0456 USH2A c.10709G > T p.Cys3570Phe D(0) Pr. D(0.996) Class C65 D 5.21 – – –
RP-0338 USH2A c.9433C > T p.Leu3145Phe D(0.02) Pos. D(0.598) Class C15 P 0.70 – 0.0001 –
RP-2113 USH2A c.5462A > G p.Lys1821Arg T(0.1) B(0.096) Class C25 P 2.00 – – –
Splice Variants
Family Gene cDNA Protein HSF BDGP AST NetGene 2 ESEFinder SPV EVS ExAC
RP-2066 PDE6A c.1620 + 1G > T splicing defect 95.1/- 0.99/- 86.85/69.73 0.82/- loss SF2/ASF – – 0.00001
RP-0040 PRCD c.74 + 1G > A splicing defect 79.8/- 0.45/- 67.08/49.96 0.7/- loss SF2/ASF – – 0.00002
Table 2.  Pathogenicity assesment of novel rare missense and splicing variants. Abbreviations: SIFT ( D: 
deleterious; T: tolerated); Polyphen (Pos.D: possibly damaging; Pr.D: probably damaging; B: benign); Align 
GVGD (Class C15 less likely pathogenic and Class C65 most likely pathogenic); Mutation taster (D: disease 
causing; P: polymorphism). PhyloP (From negative values to 1: fast-evolving sites and positive values above 1: 
conserved sites). Splicing prediction software: wild-type/mutant score. Human Splice finder (HSF), Berkeley 
Drosophila Genome Project (BDGP), Analyzer Splice Tool (AST). – means the depletion of the 5’ splice 
site. SPV: Spanish Population Variation Database. EVS: Exome Variant Server. ExAC: Exome Aggregation 
Consortium.
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families requires the hearing follow up for these patients. The RP-1543 family with mutations in ABCA4 was pre-
viously classified as arRP however, the presence of these two mutations arguing in favour of a cone-rod dystrophy 
allowed after a careful clinical evaluation its reclassification21. It is well known that at advance stages of the disease 
it is difficult to establish a precise clinical diagnosis. The family RP-1201 presented a mutation in the RP2 X-linked 
gene changing dramatically the genetic counseling for the family. In addition previous studies have demonstrated 
that around 15% of males with isolated RP carry mutations in X-linked retinal degeneration genes22.
Lastly the RP-1772 family, which carried a heterozygous RP1 mutation, was re-classified as an autosomal 
dominant RP. Although mutations in the RP1 gene have been described in both, autosomal dominant and reces-
sive RP forms23, type and location of the mutation and phenotype can help in the genetic classification. The novel 
frameshift mutation was located in the protein domain where mutations were usually found causing autosomal 
dominant RP. Also, the phenotype of the patients argues in favour of this finding due to the recessive mutations in 
the RP1 gene cause an early onset RP24. Although there was not antecedents of retinal degeneration in the family, 
we could confirm the frameshift mutation also in a non-affected sibling supporting the existence of the incom-
plete penetrance previously reported in this gene25. Thus, the identification of the genetic defect becomes increas-
ingly relevant, especially when gene-specific therapeutic approaches are becoming more promising according to 
the results of the ongoing clinical trials26.
It is important to be aware of the NGS limitations. The detection of some types of mutations could be missed 
as trinucleotide repeats, small insertions/deletions or CNV variations27. In our design, for RPGR only 70% of the 
Figure 2. CNVs analysis and MLPA profile for the three large rearrangements. Ratios below 0.7 were 
considered deletions; those above 1.2 were considered to be duplications. (A) Deletion of exons 13 and 14 
identified in the EYS gene in the RP-1929 family. (B) Deletion of exon 19 identified in the EYS gene in the RP-
1706 family. (C) Gross deletion from the exon 45 to 49 in USH2A (RP-2112).
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whole gene was covered by at least 10X. Due to the highly repetitive sequences and purine-rich regions in open 
reading frame 15 (ORF15)─ that is the last exon of the RPGR gene in which nearly 60% of disease-causing RPGR 
mutations are located─ is difficult to capture using conventional NGS technologies. However, the rest of the gene 
was greatly covered. To date other alternatives have been successfully performed to sequence ORF15 in those 
cases in which attempts at characterization by NGS had failed28.
The high coverage obtained with our panel-based NGS approach allows us to perform a CNV analysis in our 
cohort providing the genetic diagnosis for three families (3/47). Although the CNVs results could not be reliable 
when the coverage fell below 100X, this analysis should be routinely applied in targeted sequencing.
Regardless of the inheritance pattern, in well-characterized cases, the panel-based targeted sequencing is 
superior to other methods in both time and cost, which makes it an optimal approach. Compared with other 
technologies used in the past such as genotyping microarrays12, NGS has been reported to identify the genetic 
cause in 19% to 50% of arRP cases (and 50% to 82% of RP cases in general)10,29, which is significantly higher than 
the reported 11-12% for microarray screening in Spanish population.
Our results extend not only the mutational spectrum for arRP but also the population specific variants 
frequently found in our Spanish database and facilitates further interpretation of NGS panel on RD patients. 
Our cohort was selected after a previous screening with a genotyping microarray and 11 out of the 17 families 
with a previous mutated allele had a mutation in the USH2A gene enriching the percentage of USH2A muta-
tions. Therefore, our results are not representative of the frequency and distribution of the genes in the Spanish 
population.
The obtained detection rate of 57.4% supports the application of this targeted NGS strategy as an effective 
tool for the diagnosis of RP patients30 because our approach can handle the heterogeneity of the disease. Further 
improvements in NGS technologies and the discovery of novel genes involved in the disease will likely improve 
the molecular diagnosis of RP.
Methods
Patients recruitment. Patients diagnosed with RP were recruited from the Biobank of the Fundación 
Jiménez Díaz Hospital (Madrid, Spain). Diagnostic criteria for RP included night blindness and/or peripheral 
visual loss and poor visual acuity in advanced stages of the disease. Ophthalmic examinations including elect-
rorretinogram (ERG), fundus, visual field test and best-corrected visual acuity (BCVA) measurements were per-
formed on each index case.
Peripheral blood samples of index cases and their family members were collected in EDTA tubes. DNA was 
extracted from peripheral blood leukocytes with an automated DNA extractor (model BioRobotEZ1; Qiagen, 
Hilden, Germany) following the manufacturer’s instructions.
A total of 47 unrelated Spanish families with arRP or sporadic RP (sRP), previously screened for known 
mutations with a specific arRP genotyping microarray (AsperBiotech, Tartu, Estonia) were selected. The cohort 
included 24 patients with a previously identified variation (mutation or polymorphism) used as validation con-
trols and 23 without any previous genetic alteration. Informed consents were obtained from all patients and fam-
ily members involved in the study. All procedures were reviewed and approved by the Ethics Committee of the 
hospital and adhered to the tenets of the Declaration of Helsinki and further reviews (Fortaleza, 2013).
Two hundred and sixty-seven in-house whole exomes from Spanish individuals (Spanish Population 
Variations Database available in the public domain at http://bioinfo.cipf.es/apps-beta/spv/1.0.1/ and created by 
Bioinformatic Platform for Rare Diseases CIBERER-BIER, http://www.ciberer.es/bier/) without RP family history 
of RP were used as controls to evaluate the frequency of the variations found in this study.
Capture panel design. A customized Haloplex panel was designed to capture 75 RD genes (74 previously 
known and one candidate gene) of which 41 were linked to arRP (RetNet; update Sept 2015 https://sph.uth.edu/
retnet/).
The design was performed as previously described30. The capture sequences included all coding exons and 
20 bp of their flanking 5′ and 3′ intronic regions. Additionally, four known deep-intronic mutations, involving the 
Splicing
Family Gene Nucleotide change Protein Change HSF BDGP NetGene 2 ESEFinder 1000G EVS ExAC SPV Reference
RP-1874 CNGB1 c.2634 + 6G > A splicing defect
New 
cryptic 
acceptor 
site
New cryptic 
acceptor 
site
New cryptic 
acceptor site loss SRp40 – – 0.000008 – This study
Missense
Family Gene Nucleotide change Protein Change SIFT Polyphen Align GVGD Mut.Taster phyloP 1000G EVS ExAC SPV Reference
RP-1747 EYS c.8465A > G p.Tyr2822Cys Not scored Pr.D(0.997) Class C0 P 1.23 – – – – This study
RP-1747 USH2A c.5612G > A p.Gly1871Asp D(0) Pr.D(0.995) Class C65 D 2.81 0.0016 – 0.0003 – This study
Table 3.  Unsolved families carrying one pathogenic allele. Abbreviations: SIFT ( D: deleterious; T: tolerated); 
Polyphen (Pos.D: possibly damaging; Pr.D: probably damaging; B: benign); Mutation taster (D: disease causing; 
P: polymorphism). Splicing prediction software: wild-type/mutant scores. Human Splice finder (HSF), Berkeley 
Drosophila Genome Project (BDGP), Analyzer Splice Tool (AST). EVS: Exome Variant Server. ExAC: Exome 
Aggregation Consortium. SPV: Spanish Population Variation Database.
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genes CEP290, OFD1, PRPF31 and USH2A were covered. In total 1127 regions were targeted comprising 352 Kb 
of target sequence. The final design covered 99.1% of the requested target regions.
Targeted NGS approach. The HaloPlex enrichment system is based on restriction enzyme digestion of 
genomic DNA followed by hybridization of customized probes to capture regions of interest, which are subse-
quently amplified by PCR.
The sequence capture was performed following the manufacturer’s protocol (version D3, December 2012) 
for Illumina Sequencing protocol (Agilent Technologies Inc., 131 Santa Clara, CA, USA) with minor revisions as 
previously described30. Capture libraries were sequenced using the MiSeq v2 reagents kit (Illumina, San Diego, 
California, USA) on 8 runs in an Illumina MiSeq as 150 bp paired-end reads, following the manufacturer’s 
protocol.
The primary analysis, including base calling and quality scoring, was performed by the Illumina RTA software 
application.
Data analysis. Results were analyzed with two different custom pipelines: DNAnexus analysis (www.
dnanexus.com) and BaseSpace BWA Enrichment v2.1 analysis (Illumina, San Diego, California, USA). For 
both, sequence reads from Illumina MiSeq instrument were mapped to the hg19/GRCh37 human reference 
genome. The alignment and variant calling were performed using Burrows-Wheeler Aligner (BWA)-MEM31 and 
Genome Analysis Toolkit (GATK) respectively, with default parameters depending on the pipeline used. The 
CalculateHsMetrics tool in Picard was used to produce the reads and coverage statistics (www.picard.sourceforge.
net).
Single base pair coverage for the 75 genes was calculated based on the BAM files with the use of the coverage 
function of BEDtools (v2.19.1)32. The coverage on base-pair resolution was computed for the protein coding 
regions (hg19 assembly) of the NCBI RefSeq database (Release 70)33. The RefSeq transcripts were downloaded 
from the UCSC genome browser and converted to bed format by a custom Java program. For a total of 185,751 
bases the coverage was determined.
The output VCF files were annotated in order to identify and classify the disease-relevant variants using the 
GATK Variant Annotator and ENSEMBL Variant Effect Predictor v72 for the samples analyzed with DNAnexus 
and the VariantStudio Variant Analysis Software (Illumina, San Diego, California, USA) for the samples analyzed 
with the BaseSpace BWA Enrichment v2.1.
All identified variants were annotated according to the guidelines published by the Human Genome Variation 
Society (www.hgvs.org/mutnomen) and were checked in the dbSNP v132 and Human Gene Mutation Data 
(HGMD® Professional) databases.
Variant prioritization and pathogenicity assesment. Identified variants were filtered by applying the 
following prioritization criteri4,30:
(1) Variants in the coding sequence excluding intergenic, 5′ and 3′ untranslated regions or deep intronic variants 
were selected.
(2) Variants were filtered by minor allele frequency (MAF) ≤ 0.005 or without MAF value in the 1000 Genomes 
Project, Exome Variant Server (EVS) and Exome Aggregation Consortium (ExAC).
(3) Variants were checked in dbSNP132
•	 Variants with rs number and present in Human Gene Mutation Data (HGMD® Professional) and Leiden 
Open Variation Database (LOVD), were considered as known pathogenic mutations after all the refer-
ences were checked.
•	 Variants without rs number were considered as novel rare variants.
(4) Nonsense, frameshift and canonical splice-site variants were considered to be pathogenic.
(5) Missense or non-canonical splice-site novel rare variants were checked against the Spanish Population Varia-
tion Database (BIER), including 267 exomes from healthy individuals. If a given variant was not present, the 
in silico prediction was performed.
(6) To assess the pathogenesis of the missense variants, four different predictive software programs were 
used including: i) Sorting Intolerant from Tolerant (SIFT; sift.jcvi.org), ii) Polymorphism Phenotyping v2 
(Polyphen-2; genetics.bwh.harvard.edu/pph2), iii) Align GVGD (agvgd.iarc.fr/agvgd_input.php) and iv) 
Mutation Taster (www.mutationtaster.org). Variants detected in potential splice-sites were analyzed by: i) 
Human Splice Finder (HSF; www.umd.be/HSF), ii) Analyzer Splice Tool (AST; ibis.tau.ac.il/ssat/SpliceSite-
Frame.htm), iii) Berkeley Drosophila Genome Project (BDGP; www.fruitfly.org/seq_tools/splice), iv) Net-
Gene 2 (www.cbs.dtu.dk/services/NetGene2) and v) ESE Finder 3.0 (http://rulai.cshl.edu/cgi-bin/tools/ESE3/
esefinder.cgi ? process = home). Those variants predicted as damaging by at least two different prediction 
softwares were initially considered potentially pathogenic.
For those samples with a previous pathogenic variant a manual search for a second variant allele in the corre-
sponding gene was performed directly. When a second pathogenic allele was not found we applied the previous 
filtering criteria in order to find other RP genes. Variants were further prioritized according to the inheritance 
pattern.
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Data validation and segregation analysis. A total of 24 patients carrying a previous known variant (17 
mutations and 7 polymorphism) were tested as validation controls to verify the reliability of our custom NGS 
strategy.
Sanger sequencing was performed to confirm all the deleterious mutations and potentially pathogenic variants 
and to segregate them in the families. Bidirectional automatic sequencing was performed using 20-mer oligonu-
cleotide primer pairs designed by ExonPrimer software (UCSC). Primer sequences and annealing temperatures 
are available from the authors on request. The PCR products were enzymatically purified with ExoSAP-it (USB, 
Affymetrix) and sequenced using BigDye® Terminator v1.1 Cycle Sequencing Kit (Life technologies). The PCR 
products were resolved on an automated sequencer (ABI 3130xl Genetic Analyzer, Applied Biosystems). The 
results were analyzed by Staden Package software version 2.0.0 b10 (available at: staden.sourceforge.net; accessed 
September, 2014) by assembling and visualizing the aligned sequences compared with reference sequence (UCSC 
Genome Browser).
Copy-number variation analysis. Due to the very high expected coverage for all target regions sequenced 
with the Illumina MiSeq system (> 90% base-pairs covered by 100× ), a copy-number variation (CNV) analysis 
was performed. The coverage of each target region was normalized and compared against normalized data of the 
rest of the samples of the same run to obtain the ratio relative coverage34. Only those cases with a heterozygous 
pathogenic single-nucleotide mutation in a specific gene were analyzed. If the ratio fell below 0.7 it was considered 
a deletion and if it rose above 1.2 it was considered a duplication. In addition only those regions with ≥ 100× were 
selected. Following these criteria the detected CNVs were validated by multiplex ligation-dependent probe ampli-
fication (MLPA) for the affected genes. For the EYS gene, the SALSA MLPA probemix P328 was used. To confirm 
the USH2A CNV the SALSA MLPA probemixes P361 and P362 were utilized (MRC-Holland, Amsterdam, The 
Netherlands). The MLPA reaction was performed following the manufacturer’s instructions. The MLPA results 
were analyzed with the Coffalyser.Net software (MRC-Holland, Amsterdam, The Netherlands).
The validation of the putative CNVs found in CEP290, in which commercial MLPA was not available, was 
performed by a customized comparative genomic hybridization array (aCGH).
Comparative genomic hybridization array (aCGH). The customized aCGH 8 × 60 k Agilent SurePrint 
G3 CGH was designed using the Agilent eArray website (https://earray.chem.agilent.com/earray/) with an aver-
age distribution of 1 probe per 150 pb.
The processing was performed according to manufacturer’s recommendations as previously described15.
Results were analyzed by Agilent CytoGenomics software v.2.7 using default analysis method – CGH v2 with 
the ADM-2 aberration algorithm.
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This Article contains errors.
In Table 1, for Family RP-1929 the nucleotide change ‘c.9079dupA’ and protein change ‘p.Arg3027Lysfs*9’ were 
incorrectly given as ‘c.9142dupA’ and ‘p.Arg3048Lysfs*9’ respectively.
In Table 2, for Family RP-1147 the cDNA ‘c.830G > A’ and protein ‘p.Arg277Gln’ were incorrectly given as 
‘c.1037G > A’ and ‘p.Arg346Gln’ respectively.
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